Literature DB >> 30359704

Subchronic (90-day) repeated dose oral toxicity study of 2-hydroxybenzylamine acetate in rabbit.

John C Fuller1, Lisa M Pitchford2, Naji N Abumrad3, John A Rathmacher4.   

Abstract

2-hydroxybenzylamine (2-HOBA), a naturally occurring compound found in buckwheat, has potential for use as a nutrition supplement due to its ability to protect against the damaging effects of oxidative stress. In a series of rodent toxicity studies, 2-HOBA acetate was well-tolerated and did not produce any toxic effects over 28 or 90 days of repeated oral administration. However, it remained necessary to test the potential toxicity of 2-HOBA acetate in a non-rodent species. In this investigation, 2-HOBA acetate was orally administered to male and female New Zealand White Rabbits for 90 days at doses of 100, 500, and 1000 mg·kg BW-1·day-1 (n = 5 per sex/group). As previously observed in rodents, 2-HOBA acetate administration was well tolerated. No toxic effects of 2-HOBA acetate were detected in body weight, feed consumption, hematology, blood chemistry, urine chemistry, organ weights, gross pathology or histopathology. Based on these findings, the no-observed-adverse-effect-level of 2-HOBA acetate in rabbits was determined to be 1000 mg·kg BW-1·day-1, which was the highest dose tested. These results provide further support for the safety of 2-HOBA acetate administration.
Copyright © 2018 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Preclinical; Rabbit; Safety; Salicylamine; γ-Ketoaldehydes

Mesh:

Substances:

Year:  2018        PMID: 30359704     DOI: 10.1016/j.yrtph.2018.10.017

Source DB:  PubMed          Journal:  Regul Toxicol Pharmacol        ISSN: 0273-2300            Impact factor:   3.271


  3 in total

Review 1.  Isolevuglandins as mediators of disease and the development of dicarbonyl scavengers as pharmaceutical interventions.

Authors:  Sean S Davies; Linda S May-Zhang; Olivier Boutaud; Venkataraman Amarnath; Annet Kirabo; David G Harrison
Journal:  Pharmacol Ther       Date:  2019-10-16       Impact factor: 12.310

2.  First-in-human study assessing safety, tolerability, and pharmacokinetics of 2-hydroxybenzylamine acetate, a selective dicarbonyl electrophile scavenger, in healthy volunteers.

Authors:  Lisa M Pitchford; John A Rathmacher; John C Fuller; J Scott Daniels; Ryan D Morrison; Wendall S Akers; Naji N Abumrad; Venkataraman Amarnath; Patricia M Currey; L Jackson Roberts; John A Oates; Olivier Boutaud
Journal:  BMC Pharmacol Toxicol       Date:  2019-01-05       Impact factor: 2.483

3.  Safety, tolerability, and pharmacokinetics of repeated oral doses of 2-hydroxybenzylamine acetate in healthy volunteers: a double-blind, randomized, placebo-controlled clinical trial.

Authors:  Lisa M Pitchford; Patricia M Driver; John C Fuller; Wendell S Akers; Naji N Abumrad; Venkataraman Amarnath; Ginger L Milne; Sheau-Chiann Chen; Fei Ye; L Jackson Roberts; M Benjamin Shoemaker; John A Oates; John A Rathmacher; Olivier Boutaud
Journal:  BMC Pharmacol Toxicol       Date:  2020-01-06       Impact factor: 2.483

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.